Total neoadjuvant treatment for MRI-stratified high-risk rectal cancer: a single-center, single-arm, prospective Phase II trial (PKUCH-R02). (18th April 2023)

• Record Type: Journal Article
• Authors: Chen, Peng-Ju; Wang, Lin; Sun, Ting-Ting; Yao, Yun-Feng; Peng, Yi-Fan; Zhao, Jun; Zhan, Tian-Cheng; Leng, Jia–Hua; Cai, Yong; Li, Yong-Heng; Zhang, Xiao-Yan; Sun, Ying-Shi; Li, Zhong-Wu; Wang, Wei-Hu; Wu, Ai-Wen
• Is Part Of: Gastroenterology report. Volume 11(2023)
• Publication Date: 2023-04-18
• Subjects: rectal cancer -- neoadjuvant chemoradiotherapy -- MRI -- prognosis -- pathological complete response; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1093/gastro/goad017
• Languages: English
• ISSNs: 2052-0034

Abstract

Abstract: Background: Induction chemotherapy combined with neoadjuvant chemoradiotherapy has been recommended for patients with high-risk, locally advanced rectal cancer. However, the benefit of more intensive total neoadjuvant treatment (TNT) is unknown. This study aimed to assess the safety and efficacy of induction chemotherapy combined with chemoradiotherapy and consolidation chemotherapy for magnetic resonance imaging-stratified high-risk rectal cancer. Methods: This was a single-center, single-arm, prospective Phase II trial in Peking University Cancer Hospital (Beijing, China). Patients received three cycles of induction oxaliplatin and capecitabine (CapeOX) followed by chemoradiotherapy and two cycles of consolidation CapeOX. The primary end point was adverse event rate and the second primary end points were 3-year disease-free survival rate, completion of TNT, and pathological downstaging rate. Results: Between August 2017 and August 2018, 68 rectal cancer patients with at least one high risk factor (cT3c/3d/T4a/T4b, cN2, mesorectal fascia involvement, or extramural venous invasion involvement) were enrolled. The overall compliance of receiving the entire treatment was 88.2% (60/68). All 68 patients received induction chemotherapy, 65 received chemoradiotherapy, and 61 received consolidation chemotherapy. The Grade 3–4 adverse event rate was 30.8% (21/68). Nine patients achieved clinical complete response and then watch and wait. Five patients (7.4%) developed distant metastasis during TNT and received palliative chemotherapy. Fifty patients underwent surgical resection. The complete response rate was 27.9%. After a median follow-up of 49.2 months, the overall 3-year disease-free survival rate was 69.7%. Conclusions: For patients with high-risk rectal cancer, this TNT regimen can achieve favorable survival and complete response rates but with high toxicity. However, it is necessary to pay attention to the possibility of distant metastasis during the long treatment period.